drugset
drugset / Trial / NCT00645281

A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.

NCT00645281 ↗

Phase 4 Completed 896 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of tolterodine in impacting the primary symptom or complaint of patients with OAB.

Timeline

Start
2004-03
Primary completion
—
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tolterodine Small molecule 4 mg —

Indications

overactive bladder